 1Q22 Added 19,673 New Subscribers Revenues Up 12.2 YoY to RMB315.2 Million 48.8 Million Gross Profit Up 12.6 YoY to RMB267.3 Million 41.4 Million Operating Income Up 17.3 YoY to RMB156.6 Million 24.2 Million Non-GAAP Operating Income Up 15.5 YoY to RMB168.5 Million 26.1 Million Conference Call to be Held on August 31, 2021, at 8:00 a.m. ET HONG KONG, Aug. 30, 2021 PRNewswire -- Global Cord Blood Corporation NYSE: CO GCBC or the Company, Chinas leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the first quarter of fiscal 2022, ended June 30, 2021. 